Research Analysts Issue Forecasts for Alector, Inc.’s Q1 2025 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – William Blair issued their Q1 2025 earnings estimates for Alector in a report issued on Thursday, August 8th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.47) per share for the quarter. The consensus estimate for Alector’s current full-year earnings is ($1.93) per share. William Blair also issued estimates for Alector’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.44) EPS, FY2027 earnings at $2.06 EPS and FY2028 earnings at $25.50 EPS.

Several other equities research analysts have also recently weighed in on ALEC. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a research report on Monday, July 29th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Alector in a research report on Thursday, June 20th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Alector currently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Alector Price Performance

NASDAQ:ALEC opened at $5.10 on Friday. The company has a market cap of $491.56 million, a price-to-earnings ratio of -3.70 and a beta of 0.72. Alector has a 1 year low of $3.66 and a 1 year high of $8.90. The stock’s 50 day simple moving average is $5.08 and its two-hundred day simple moving average is $5.61.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The firm had revenue of $15.08 million during the quarter, compared to analyst estimates of $16.04 million. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. During the same quarter last year, the business posted $0.02 earnings per share.

Insider Transactions at Alector

In other Alector news, CEO Arnon Rosenthal sold 25,135 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the transaction, the chief executive officer now owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Alector news, CFO Marc Grasso sold 6,920 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $33,216.00. Following the transaction, the chief financial officer now directly owns 138,037 shares in the company, valued at approximately $662,577.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arnon Rosenthal sold 25,135 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now owns 1,975,245 shares of the company’s stock, valued at $9,481,176. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,095 shares of company stock worth $192,456. 9.10% of the stock is currently owned by company insiders.

Institutional Trading of Alector

A number of hedge funds have recently added to or reduced their stakes in ALEC. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Alector by 3.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 61,239 shares of the company’s stock worth $489,000 after purchasing an additional 2,120 shares during the period. Federated Hermes Inc. raised its stake in Alector by 4.1% in the second quarter. Federated Hermes Inc. now owns 68,538 shares of the company’s stock worth $311,000 after buying an additional 2,709 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Alector by 24.1% during the first quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock worth $119,000 after buying an additional 3,827 shares during the period. American International Group Inc. boosted its position in Alector by 13.0% during the 1st quarter. American International Group Inc. now owns 35,655 shares of the company’s stock valued at $215,000 after acquiring an additional 4,105 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its holdings in shares of Alector by 2.3% in the 4th quarter. Rafferty Asset Management LLC now owns 190,911 shares of the company’s stock valued at $1,523,000 after acquiring an additional 4,287 shares during the period. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.